Integrating Seropharmacology, Network Pharmacology, and Single‐Cell Transcriptomics to Decipher the Dual Anti‐Tumor Mechanisms of Astragalus– Curcuma zedoaria in Lung Squamous Cell Carcinoma
Biomedical Chromatography · 2026-07 · 40 (7)
DOI: 10.1002/bmc.70482 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 09.06.2026. Verfasst von Luhang Yu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Oncology, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Astragalus Plant, Lung Neoplasms, Carcinoma, Squamous Cell, Curcuma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
This study sought to elucidate the antitumor mechanisms of the traditional herbal combination Astragalus– Curcuma zedoaria (A–C) in lung squamous cell carcinoma (LUSC). Drug‐containing serum was prepared from mice administered an A–C decoction, and serum‐absorbed bioactive components were identified using high‐resolution mass spectrometry. To investigate potential targets and pathways within the tumor immune microenvironment, network pharmacology analysis was integrated with bulk transcriptomic data from TCGA‐LUSC and single‐cell RNA sequencing (scRNA‐seq). The analytical methodologies employed included differential gene expression analysis, weighted gene co‐expression network analysis (WGCNA), functional enrichment analysis, and molecular docking. The scRNA‐seq data identified 22 distinct cell clusters, with correlation analysis suggesting that A–C primarily exerts its effects through vascular endothelial cells. Among the serum‐derived components, demethoxycurcumin—a principal curcuminoid from C. zedoaria —demonstrated the highest binding affinity with the TEK receptor tyrosine kinase (−7.5 kcal/mol), indicating its potential role in modulating endothelial function and vascular–immune interactions. In conclusion, the A–C combination exhibits a synergistic effect in lung squamous cell carcinoma (LUSC) by modulating differentially expressed genes, with demethoxycurcumin identified as a pivotal bioactive compound targeting TEK. These results elucidate novel dual antitumor mechanisms of the A–C herbal pair, achieved through the regulation of the vascular–immune microenvironment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Senior Department of Oncology, Chinese PLA General Hospital, Beijing, China.
- Department of Oncology, Beijing Chaoyang Intergrative Medicine Rescue and First Aid Hospital, Beijing, China.
- Department of Traditional Chinese Medicine, The Ninth Medical Center of Chinese PLA General Hospital, Beijing, China.
- Department of Traditional Chinese Medicine, The Sixth Medical Center, General Hospital of Chinese PLA, Beijing, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yu, L., Dong, X., Yang, Q., & Dou, Y. (2026). Integrating Seropharmacology, Network Pharmacology, and Single‐Cell Transcriptomics to Decipher the Dual Anti‐Tumor Mechanisms of Astragalus– Curcuma zedoaria in Lung Squamous Cell Carcinoma. Biomedical Chromatography, 40(7). https://doi.org/10.1002/bmc.70482
Vancouver
Yu L, Dong X, Yang Q, Dou Y. Integrating Seropharmacology, Network Pharmacology, and Single‐Cell Transcriptomics to Decipher the Dual Anti‐Tumor Mechanisms of Astragalus– Curcuma zedoaria in Lung Squamous Cell Carcinoma. Biomedical Chromatography. 2026;40(7). doi:10.1002/bmc.70482
BibTeX
@article{Yu2026,
author = {Yu, Luhang and Dong, Xueshan and Yang, Qianyu and Dou, Yongqi},
title = {Integrating Seropharmacology, Network Pharmacology, and Single‐Cell Transcriptomics to Decipher the Dual Anti‐Tumor Mechanisms of Astragalus– Curcuma zedoaria in Lung Squamous Cell Carcinoma},
journal = {Biomedical Chromatography},
year = {2026},
volume = {40},
number = {7},
doi = {10.1002/bmc.70482}
}
EUVIMED